Immunostimulatory Oligonucleotides

Abstract

RNA-protein interactions have been characterized often. Above all, the proteins which are associated with the studied RNA should be precisely identified. The pharmaceutical compositions containing nucleic acids and/or other compounds can be administered by any suitable route for administering medications. The immunostimulatory oligonucleotides play the role of antisense drugs which are being researched to treat cancers (including lung cancer, colorectal carcinoma, pancreatic carcinoma, malignant glioma and malignant melanoma), diabetes, Amyotrophic lateral sclerosis (ALS), and diseases such as asthma and arthritis with an inflammatory component. The immunostimulatory oligonucleotides may contain one or more natural or unnatural amino acid residues which are connected to the polymer by peptide (amide) linkages. The vaccine against cancer which has been produced during this work can be prophylactic or therapeutic. Since most studies so far have been performed with first-generation antisense oligonucleotides (ODNs), it is interesting to observe how second-generation immune stimulatory drug candidates with enhanced potency and efficacy can further improve the utility of this class of therapeutic agents. The aim of this article is to review most significant patents on immunostimulatory oligonucleotides.

IGF-I Antisense and Triple-Helix Gene Therapy of Glioblastoma

“…avastin), targeting growth factors and their receptors [63][64][65][66]. The new therapies are now focusing on technology of inhibitors and antigene techniques (antisense or triple helix) used alone or combined with drug treatment [67][68][69][70][71]. A pharmacological strategy -the use of temozolomide introduced by R. Stupp, has offered a new hope for treatment of glioblastoma.…”

Modulating Immune Response with Nucleic Acid Nanoparticles

“…In general, there are two main strategies that are used to stimulate immune response. The first and most common way is to employ immunostimulatory oligonucleotides [60,61,62,63], and the second is to use various NANPs as immunostimulators, depending on their shapes, sequences, and nucleic acid composition [8,10,11]. Below, we briefly describe both approaches.…”